Berenberg Bank Reaffirms “Buy” Rating for Abcam (LON:ABC)
Berenberg Bank restated their buy rating on shares of Abcam (LON:ABC) in a report published on Monday, Digital Look reports. They currently have a GBX 1,330 ($17.38) target price on the stock.
Separately, Peel Hunt reaffirmed an add rating and set a GBX 1,300 ($16.99) price target (down previously from GBX 1,430 ($18.69)) on shares of Abcam in a research note on Monday.
Abcam stock opened at GBX 1,146 ($14.97) on Monday. Abcam has a 12-month low of GBX 1,006 ($13.15) and a 12-month high of GBX 1,523 ($19.90). The company has a market capitalization of $2.38 billion and a price-to-earnings ratio of 41.08. The firm’s fifty day moving average price is GBX 1,222.48 and its 200 day moving average price is GBX 1,292.48.
In related news, insider Alan Thomas Hirzel acquired 4,250 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was bought at an average cost of GBX 1,139 ($14.88) per share, with a total value of £48,407.50 ($63,252.97).
Abcam Company Profile
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
Featured Article: Why do companies issue monthly dividends?
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.